Stifel Financial Corp bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,314 shares of the biotechnology company’s stock, valued at approximately $643,000.

Other large investors have also recently added to or reduced their stakes in the company. APG Asset Management N.V. acquired a new position in shares of United Therapeutics during the 1st quarter valued at about $80,654,000. Robeco Institutional Asset Management B.V. lifted its stake in United Therapeutics by 3,487.9% during the second quarter. Robeco Institutional Asset Management B.V. now owns 524,257 shares of the biotechnology company’s stock worth $63,434,000 after purchasing an additional 509,645 shares during the last quarter. Marshall Wace North America L.P. lifted its stake in United Therapeutics by 922.1% during the second quarter. Marshall Wace North America L.P. now owns 318,336 shares of the biotechnology company’s stock worth $38,519,000 after purchasing an additional 287,192 shares during the last quarter. Wedge Capital Management L L P NC bought a new position in United Therapeutics during the second quarter worth $34,709,000. Finally, Nuveen Asset Management LLC lifted its stake in United Therapeutics by 48.9% during the first quarter. Nuveen Asset Management LLC now owns 776,413 shares of the biotechnology company’s stock worth $73,624,000 after purchasing an additional 255,101 shares during the last quarter. Institutional investors own 94.37% of the company’s stock.

Shares of United Therapeutics stock opened at $100.45 on Monday. The firm has a market cap of $4.46 billion, a price-to-earnings ratio of 10.31 and a beta of 0.74. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.43 and a quick ratio of 7.08. United Therapeutics Co. has a 52-week low of $75.58 and a 52-week high of $127.79. The stock has a 50-day simple moving average of $106.70 and a 200-day simple moving average of $108.64.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $2.41 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.41. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. The business had revenue of $362.00 million during the quarter, compared to analyst estimates of $339.97 million. During the same period in the previous year, the company earned $3.63 EPS. The firm’s revenue was down 3.1% on a year-over-year basis. As a group, equities research analysts predict that United Therapeutics Co. will post 9.52 earnings per share for the current year.

In related news, CEO Martine A. Rothblatt sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $120.73, for a total value of $1,207,300.00. Following the transaction, the chief executive officer now directly owns 10,140 shares of the company’s stock, valued at approximately $1,224,202.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 40,000 shares of company stock worth $4,786,000 over the last three months. 10.90% of the stock is owned by company insiders.

A number of equities research analysts have issued reports on UTHR shares. TheStreet cut United Therapeutics from a “b” rating to a “c” rating in a research note on Wednesday, July 29th. BidaskClub cut United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. HC Wainwright raised their target price on United Therapeutics from $85.00 to $125.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Cowen reiterated a “buy” rating and issued a $145.00 target price on shares of United Therapeutics in a research note on Friday, June 12th. Finally, JPMorgan Chase & Co. started coverage on United Therapeutics in a research note on Monday, September 14th. They issued an “overweight” rating on the stock. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $141.67.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Story: How to Profit and Limit Losses With Stop Orders

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.